Sirtratumab vedotin
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].
Product Specifications
CAS Number
1824663-83-3
Product Name Alternative
AGS15E; ASG-15ME; 1vcMMAE
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
96.42
Solubility
H2O
Smiles
[Sirtratumabvedotin]
References & Citations
[1]Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15 (6) :1301-10.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RR203418L3 10 µg
RGD1563815 (NM_001127556) Rat Tagged Lenti ORF Clone
Sign In for Pricing
View Details 
RC201095L1V 200 µL
MDH2 (NM_005918) Human Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details